What is the primary financial impact disclosed in this filing?

The primary financial impact disclosed is an estimated $46 million pre-tax charge related to acquired in-process research and development, upfront, and milestone expenses for the second quarter of 2025. This is expected to decrease both GAAP and non-GAAP earnings per diluted share by approximately $0.26.

Why is Biogen incurring these R&D-related expenses?

These expenses are associated with collaboration and license agreements, which can include upfront and milestone payments, as well as premiums on equity securities and asset acquisitions of acquired in-process R&D. The specific nature of the transactions leading to this Q2 charge is not detailed in this filing.

Are these Q2 2025 results finalized?

No, the results for the quarter ended June 30, 2025, have not been finalized and are subject to the company's financial statement closing procedures. Biogen cautions that there can be no assurance that the final reported results will not differ from these preliminary estimates.

Does this expense impact both GAAP and non-GAAP earnings?

Yes, the filing explicitly states that the estimated charge of approximately $0.26 per share is expected to impact both GAAP and non-GAAP net income per diluted share for the second quarter of 2025.

BIIB 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 7, 2025. Cited figures are marked; the original filing is the authoritative source.

Biogen Inc. (BIIB) has issued a Current Report on Form 8-K disclosing anticipated financial results for the second quarter of 2025.

The company expects to incur approximately $46 million^a in acquired in-process research and development, upfront, and milestone expenses on a pre-tax basis. This charge is estimated to reduce both GAAP and non-GAAP earnings per diluted share by approximately $0.26 for the quarter.

02—Key points

Key Highlights

Biogen anticipates a $46 million pre-tax charge for acquired in-process R&D, upfront, and milestone expenses in Q2 2025.
This expense is expected to reduce Q2 2025 GAAP and non-GAAP EPS by approximately $0.26 per share.
The company has begun presenting these specific R&D-related expenses as a separate line item in its income statements.
Biogen does not forecast these expenses due to their inherent uncertainty in occurrence, magnitude, and timing.
The reported figures are preliminary and subject to financial statement closing procedures, with no assurance that final results will not differ.
The filing includes a standard cautionary note regarding forward-looking statements and associated risks and uncertainties.

03—Questions

Frequently Asked Questions

What is the primary financial impact disclosed in this filing?
The primary financial impact disclosed is an estimated $46 million pre-tax charge related to acquired in-process research and development, upfront, and milestone expenses for the second quarter of 2025. This is expected to decrease both GAAP and non-GAAP earnings per diluted share by approximately $0.26.
Why is Biogen incurring these R&D-related expenses?
These expenses are associated with collaboration and license agreements, which can include upfront and milestone payments, as well as premiums on equity securities and asset acquisitions of acquired in-process R&D. The specific nature of the transactions leading to this Q2 charge is not detailed in this filing.
Are these Q2 2025 results finalized?
No, the results for the quarter ended June 30, 2025, have not been finalized and are subject to the company's financial statement closing procedures. Biogen cautions that there can be no assurance that the final reported results will not differ from these preliminary estimates.
Does this expense impact both GAAP and non-GAAP earnings?
Yes, the filing explicitly states that the estimated charge of approximately $0.26 per share is expected to impact both GAAP and non-GAAP net income per diluted share for the second quarter of 2025.

04—Continue

← View all 8-K filings